Key clinical point: Guselkumab effectively resolved dactylitis in the majority of patients with psoriatic arthritis (PsA), with improvements sustained through 1 year, which in turn improved other clinical outcomes.
Major finding: At week 24, a significantly higher proportion of patients receiving guselkumab every 4 or 8 weeks (Q4W or Q8W) vs placebo (63.5% or 59.4% vs 42.2%, respectively; P < .05) achieved dactylitis resolution; approximately 80% of patients receiving guselkumab achieved ≥70% improvement in dactylitis severity score by week 52. Patients with resolved dactylitis at week 24 were more likely to achieve American College of Rheumatology 50 response and other clinical outcomes ( P < .05).
Study details: This pooled analysis included 1120 patients with active PsA from the phase 3 DISCOVER-1 and DISCOVER-2 studies who were randomly assigned to receive 100 mg guselkumab Q4W or Q8W or placebo.
Disclosures: This study was supported by Janssen Research & Development, LLC. Several authors declared being employees, holding patents, or having other ties with Janssen or other sources.
Source: McGonagle D et al. Guselkumab, a selective Interleukin-23 p19 subunit Inhibitor, resolves dactylitis in patients with active psoriatic arthritis: Pooled results through week 52 from two phase 3 studies. ACR Open Rheumatol. 2023 (Mar 7). Doi: 10.1002/acr2.11537